ArticleCureus2026
The Effect of Early Anticoagulation Therapy in Acute Pulmonary Embolism: A Retrospective Cohort Study in the Emergency Department.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methylation in the TAC1 Gene Promoter Is Associated with the Transition from Acute Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pulmonary embolism (PE) is a critical emergency condition that can lead to rapid hemodynamic compromise and death if not treated promptly.
objectiveTo assess whether initiating anticoagulation within two hours of emergency department (ED) presentation improves in-hospital outcomes in patients with acute pulmonary embolism.
methodsThis retrospective cohort study was conducted at Fauji Foundation Hospital, Rawalpindi, from December 2024 to June 2025. A total of 345 adult patients diagnosed with acute PE between January 2020 and December 2024 were included. Patients were divided into two cohorts: early anticoagulation and delayed anticoagulation (initiated after four hours). Clinical data, including demographics, comorbidities, hemodynamic parameters, laboratory findings, imaging results, and treatment outcomes, were analyzed.
resultsOut of 345 patients, 192 (55.6%) received early and 153 (44.4%) delayed anticoagulation. The mean age was 54.8 ± 15.2 years, with 215 (62.3%) males. Mortality was significantly lower in the early group, 14 patients (7.3%), compared to 26 patients (17.0%) in the delayed group (p = 0.006). Early anticoagulation also reduced recurrent thromboembolism, occurring in seven patients (3.6%) versus 14 patients (9.2%) in the delayed group (p = 0.03), as well as ICU admissions-47 patients (24.5%) versus 59 patients (38.6%), respectively (p = 0.008). The mean hospital stay was significantly shorter in the early group (5.8 ± 2.9 days) than in the delayed group (8.4 ± 3.6 days, p < 0.001). No significant difference in major bleeding events was observed between groups (p = 0.48). Conclusion: It is concluded that initiating anticoagulation within two hours of presentation significantly improves survival, decreases recurrence, and shortens hospital stay without increasing bleeding risk. Emergency departments should prioritize rapid diagnostic and treatment pathways to enable early anticoagulation, particularly in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.